Side Effects of Perioperative Intravesical Treatment and Treatment Strategies for These Side Effects

Urologic Clinics of North America

Volumn 40, Issue 2, 2013, Pages 197-210

  Griffin, Joshua G ^a   Holzbeierlein, Jeff ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

Bladder; Complications; Intravesical chemotherapy; Management; Non muscle invasive; Side effects; Superficial; Toxicity

Indexed keywords

ANTIHISTAMINIC AGENT; ANTINEOPLASTIC AGENT; APAZIQUONE; BELLADONNA ALKALOID PLUS OPIATE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; GEMCITABINE; MITOMYCIN; PACLITAXEL; PHENAZOPYRIDINE; PIRARUBICIN; PLACEBO; THIOTEPA; VALRUBICIN;

ALLERGIC URTICARIA; ALOPECIA; APLASTIC ANEMIA; BLADDER CALCIFICATION; BLADDER CANCER; BLADDER DISEASE; BLADDER PERFORATION; BLADDER ULCERATION; BLADDER WALL ULCERATION; BONE MARROW SUPPRESSION; CALCIFICATION; CANCER CHEMOTHERAPY; CARDIOMYOPATHY; CARDIOTOXICITY; CHEMICAL CYSTITIS; CYSTITIS; CYSTOGRAPHY; DISEASE SEVERITY; DIZZINESS; DRUG ABSORPTION; DRUG ADMINISTRATION ROUTE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ERUPTION; DRUG EXTRAVASATION; DRUG WITHDRAWAL; DYSURIA; FAT NECROSIS; FEVER; GASTROINTESTINAL SYMPTOM; HEMATOLOGIC MALIGNANCY; HEMOLYTIC UREMIC SYNDROME; HUMAN; INDUCTION CHEMOTHERAPY; LEUKOPENIA; LIPOPHILICITY; LIVER DISEASE; LUNG TOXICITY; MALAISE; MOLECULAR WEIGHT; NECROSIS; NEPHROTOXICITY; NON MUSCLE INVASIVE BLADDER CANCER; OFF LABEL DRUG USE; PAIN; PATIENT COMFORT; PEROPERATIVE COMPLICATION; PH; PRIORITY JOURNAL; REVIEW; SKIN ALLERGY; SKIN TOXICITY; SURGICAL TECHNIQUE; SYSTEMIC THERAPY; THROMBOCYTOPENIA; TISSUE NECROSIS; TRANSMURAL NECROSIS; ULCER; UNSPECIFIED SIDE EFFECT; URINARY URGENCY; WOUND HEALING IMPAIRMENT;

ADMINISTRATION, INTRAVESICAL; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; DRUG TOXICITY; HUMANS; PERIOPERATIVE CARE; URINARY BLADDER NEOPLASMS;

EID: 84876738346     PISSN: 00940143     EISSN: 1558318X     Source Type: Journal    
DOI: 10.1016/j.ucl.2013.01.005     Document Type: Review

References (79)

1. Sylvester R.J., Oosterlinck W., van der Meijden A.P. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J Urol 2004, 171(6):2186-2190.
2. Hall M.C., Chang S.S., Dalbagni G., et al. Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J Urol 2007, 178(6):2314-2330.
3. Babjuk M., Oosterlinck W., Sylvester R., et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol 2008, 54(2):303-314.
4. Mishina T., Watanabe H., Kobayashi T., et al. Absorption of anticancer drugs through bladder epithelium. Urology 1986, 27(2):148-157.
5. Lum B.L. Intravesical chemotherapy of superficial bladder cancer. Recent Results Cancer Res 1983, 85:3-36.
6. Thrasher J.B., Crawford E.D. Complications of intravesical chemotherapy. Urol Clin North Am 1992, 19(3):529-539.
7. Paz M.M., Zhang X., Lu J., et al. A new mechanism of action for the anticancer drug mitomycin C: mechanism-based inhibition of thioredoxin reductase. Chem Res Toxicol 2012, 25(7):1502-1511.
8. Bradner W.T. Mitomycin C: a clinical update. Cancer Treat Rev 2001, 27(1):35-50.
9. Zatkone Puskas G. Az extravazacio jelentosege az onkologiai apolasban. Magy Onkol 2008, 52(1):75-80. [in Hungarian].
10. Goolsby T.V., Lombardo F.A. Extravasation of chemotherapeutic agents: prevention and treatment. Semin Oncol 2006, 33(1):139-143.
11. Albanell J., Baselga J. Systemic therapy emergencies. Semin Oncol 2000, 27(3):347-361.
12. Bregman C.L., Buroker R.A., Bradner W.T., et al. Cardiac, renal, and pulmonary toxicity of several mitomycin derivatives in rats. Fundam Appl Toxicol 1989, 13(1):46-64.
13. Coetmeur D., Briens E., Le Breton-Belleguic C., et al. Pneumopathie interstitielle et mitomycine C. A propos d'un cas avec etude du lavage broncho-alveolaire. Rev Pneumol Clin 1995, 51(1):36-40. [in French].
14. Doll D.C., Ringenberg Q.S., Yarbro J.W. Vascular toxicity associated with antineoplastic agents. J Clin Oncol 1986, 4(9):1405-1417.
15. Janeiro Pais J.M., Casas Agudo V.P., Lopez Garcia D., et al. Mitomicina C endovesical y fibrosis pulmonar. Actas Urol Esp 2009, 33(7):822-825. [in Spanish].
16. Klein D.S., Wilds P.R. Pulmonary toxicity of antineoplastic agents: anaesthetic and postoperative implications. Can Anaesth Soc J 1983, 30(4):399-405.
17. Linette D.C., McGee K.H., McFarland J.A. Mitomycin-induced pulmonary toxicity: case report and review of the literature. Ann Pharmacother 1992, 26(4):481-484.
18. Liu K., Mittelman A., Sproul E.E., et al. Renal toxicity in man treated with mitomycin C. Cancer 1971, 28(5):1314-1320.
19. Simon P., Herve J.P., Ramee M.P., et al. La nephrotoxicite de la mitomycine C. Trois nouvelles observations et revue de la litterature. Nephrologie 1982, 3(4):152-157. [in French].
20. Crocker J., Jones E.L. Haemolytic-uraemic syndrome complicating long-term mitomycin C and 5-fluorouracil therapy for gastric carcinoma. J Clin Pathol 1983, 36(1):24-29.
21. Ravikumar T.S., Sibley R., Reed K., et al. Renal toxicity of mitomycin-C. Am J Clin Oncol 1984, 7(3):279-285.
22. Valavaara R., Nordman E. Renal complications of mitomycin C therapy with special reference to the total dose. Cancer 1985, 55(1):47-50.
23. Verwey J., de Vries J., Pinedo H.M. Mitomycin C-induced renal toxicity, a dose-dependent side effect?. Eur J Cancer Clin Oncol 1987, 23(2):195-199.
24. Wientjes M.G., Dalton J.T., Badalament R.A., et al. Bladder wall penetration of intravesical mitomycin C in dogs. Cancer Res 1991, 51(16):4347-4354.
25. Wientjes M.G., Badalament R.A., Wang R.C., et al. Penetration of mitomycin C in human bladder. Cancer Res 1993, 53(14):3314-3320.
26. Wajsman Z., Dhafir R.A., Pfeffer M., et al. Studies of mitomycin C absorption after intravesical treatment of superficial bladder tumors. J Urol 1984, 132(1):30-33.
27. Sarna G.P., Champlin R., Wells J., et al. Phase I study of high-dose mitomycin with autologous bone marrow support. Cancer Treat Rep 1982, 66(2):277-282.
28. Gewirtz D.A. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol 1999, 57(7):727-741.
29. Chai M., Wientjes M.G., Badalament R.A., et al. Pharmacokinetics of intravesical doxorubicin in superficial bladder cancer patients. J Urol 1994, 152(2 Pt 1):374-378.
30. Plosker G.L., Faulds D. Epirubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cancer chemotherapy. Drugs 1993, 45(5):788-856.
31. Koga H., Kuroiwa K., Yamaguchi A., et al. A randomized controlled trial of short-term versus long-term prophylactic intravesical instillation chemotherapy for recurrence after transurethral resection of Ta/T1 transitional cell carcinoma of the bladder. J Urol 2004, 171(1):153-157.
32. Tsushima T., Miyaji Y., Noda M., et al. Absorption of epirubicin instilled intravesically immediately after transurethral resection of superficial bladder cancer. Urol Int 1998, 60(3):161-164.
33. Shang P.F., Kwong J., Wang Z.P., et al. Intravesical Bacillus Calmette-Guerin versus epirubicin for Ta and T1 bladder cancer. Cochrane Database Syst Rev 2011, (5). CD006885.
34. Yamamoto Y., Nasu Y., Saika T., et al. The absorption of pirarubicin instilled intravesically immediately after transurethral resection of superficial bladder cancer. BJU Int 2000, 86(7):802-804.
35. Dinney C.P., Greenberg R.E., Steinberg G.D. Intravesical valrubicin in patients with bladder carcinoma in situ and contraindication to or failure after bacillus Calmette-Guerin. Urol Oncol 2012, [Epub ahead of print].
36. Niell H.B., Hunter R.F., Herrod H.G., et al. Effects of N-trifluoroacetyladriamycin-14-valerate (AD-32) on human bladder tumor cell lines. Cancer Chemother Pharmacol 1987, 19(1):47-52.
37. Greenberg R.E., Bahnson R.R., Wood D., et al. Initial report on intravesical administration of N-trifluoroacetyladriamycin-14-valerate (AD 32) to patients with refractory superficial transitional cell carcinoma of the urinary bladder. Urology 1997, 49(3):471-475.
38. Patterson A.L., Greenberg R.E., Weems L., et al. Pilot study of the tolerability and toxicity of intravesical valrubicin immediately after transurethral resection of superficial bladder cancer. Urology 2000, 56(2):232-235.
39. Jones H.C., Swinney J. Thiotepa in the treatment of tumours of the bladder. Lancet 1961, 2:615-618.
40. Lunglmayr G., Czech K. Absorption studies on intraluminal thio-tepa for topical cytostatic treatment of low-stage bladder tumors. J Urol 1971, 106:72-74.
41. Soloway M.S., Ford K.S. Thiotepa-induced myelosuppression: review of 670 bladder instillations. J Urol 1983, 130(5):889-891.
42. Mini E., Nobili S., Caciagli B., et al. Cellular pharmacology of gemcitabine. Ann Oncol 2006, 17(Suppl 5):v7-v12.
43. Böhle A., Leyh H., Frei C., et al. Single postoperative instillation of gemcitabine in patients with non-muscle-invasive transitional cell carcinoma of the bladder: a randomised, double-blind, placebo-controlled phase III multicentre study. Eur Urol 2009, 56(3):495-503.
44. Maffezzini M., Campodonico F., Puntoni M., et al. Systemic absorption and pharmacokinetics of single-dose intravesical gemcitabine after transurethral resection of the bladder in non-muscle-invasive bladder cancer. Urology 2009, 74(5):1078-1083.
45. Li D., Gan Y., Wientjes M.G., et al. Distribution of DT-diaphorase and reduced nicotinamide adenine dinucleotide phosphate: cytochrome p450 oxidoreductase in bladder tissues and tumors. J Urol 2001, 166(6):2500-2505.
46. Hendricksen K., Gleason D., Young J.M., et al. Safety and side effects of immediate instillation of apaziquone following transurethral resection in patients with nonmuscle invasive bladder cancer. J Urol 2008, 180(1):116-120.
47. Tolley D.A., Parmar M.K., Grigor K.M., et al. The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of follow up. J Urol 1996, 155(4):1233-1238.
48. Solsona E., Iborra I., Ricos J.V., et al. Effectiveness of a single immediate mitomycin C instillation in patients with low risk superficial bladder cancer: short and long-term followup. J Urol 1999, 161(4):1120-1123.
49. Bouffioux C., Kurth K.H., Bono A., et al. Intravesical adjuvant chemotherapy for superficial transitional cell bladder carcinoma: results of 2 European Organization for Research and Treatment of Cancer randomized trials with mitomycin C and doxorubicin comparing early versus delayed instillations and short-term versus long-term treatment. European Organization for Research and Treatment of Cancer Genitourinary Group. J Urol 1995, 153(3 Pt 2):934-941.
50. Mostafid A.H., Rajkumar R.G., Stewart A.B., et al. Immediate administration of intravesical mitomycin C after tumour resection for superficial bladder cancer. BJU Int 2006, 97(3):509-512.
51. Oosterlinck W., Kurth K.H., Schroder F., et al. A prospective European Organization for Research and Treatment of Cancer Genitourinary Group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single stage Ta, T1 papillary carcinoma of the bladder. J Urol 1993, 149(4):749-752.
52. Ali-el-Dein B., el-Baz M., Aly A.N., et al. Intravesical epirubicin versus doxorubicin for superficial bladder tumors (stages pTa and pT1): a randomized prospective study. J Urol 1997, 158(1):68-73. [discussion: 73-4].
53. Okamura K., Ono Y., Kinukawa T., et al. Randomized study of single early instillation of (2'R)-4'-O-tetrahydropyranyl-doxorubicin for a single superficial bladder carcinoma. Cancer 2002, 94(9):2363-2368.
54. The effect of intravesical thiotepa on the recurrence rate of newly diagnosed superficial bladder cancer. An MRC Study. MRC Working Party on Urological Cancer. Br J Urol 1985, 57(6):680-685.
55. Stoehr B., Mueller T., Granig T., et al. Increasing patient comfort by optimized postoperative administration of intravesical mitomycin C. BJU Int 2008, 102(11):1556-1559.
56. Doherty A.P., Trendell-Smith N., Stirling R., et al. Perivesical fat necrosis after adjuvant intravesical chemotherapy. BJU Int 1999, 83(4):420-423.
57. Branchereau J., Luyckx F., Hitier M., et al. Necrose vesicale dans les suites d'une instillation postoperatoire precoce (Ipop) de mitomycine C. Prog Urol 2011, 21(2):151-153. [in French].
58. Fazlioglu A., Tandogdu Z., Kurtulus F.O., et al. Perivesical inflammation and necrosis due to mitomycin C instillation after transurethral resection of bladder tumor: we must be vigilant!. Urol Int 2009, 83(3):362-363.
59. Cliff A.M., Romaniuk C.S., Parr N.J. Perivesical inflammation after early mitomycin C instillation. BJU Int 2000, 85(4):556-557.
60. Nieuwenhuijzen J.A., Bex A., Horenblas S. Unusual complication after immediate postoperative intravesical mitomycin C instillation. Eur Urol 2003, 43(6):711-712.
61. Balbay M.D., Cimentepe E., Unsal A., et al. The actual incidence of bladder perforation following transurethral bladder surgery. The Journal of Urology 2005, 17(6):2260-2262.
62. Oddens J.R., van der Meijden A.P., Sylvester R. One immediate postoperative instillation of chemotherapy in low risk Ta, T1 bladder cancer patients. Is it always safe?. Eur Urol 2004, 46(3):336-338.
63. Dangle P.P., Wang W.P., Pohar K.S. Vesicoenteric, vesicovaginal, vesicocutaneous fistula -an unusual complication with intravesical mitomycin. Can J Urol 2008, 15(5):4269-4272.
64. Shapiro O., Jones K., Wang C., et al. Risk of post-operative intravesical mitomycin C instillation following transurethral bladder tumor resection. Can J Urol 2006, 13(6):3317-3320.
65. Colver G.B., Inglis J.A., McVittie E., et al. Dermatitis due to intravesical mitomycin C: a delayed-type hypersensitivity reaction?. Br J Dermatol 1990, 122(2):217-224.
66. de Groot A.C., Conemans J.M. Systemic allergic contact dermatitis from intravesical instillation of the antitumor antibiotic mitomycin C. Contact Dermatitis 1991, 24(3):201-209.
67. Kunkeler L., Nieboer C., Bruynzeel D.P. Type III and type IV hypersensitivity reactions due to mitomycin C. Contact Dermatitis 2000, 42(2):74-76.
68. Okumura A., Oishi N., Kaji K., et al. Drug eruption due to intravesical instillations of both epirubicin and mitomycin C. J Dermatol 2009, 36(7):419-422.
69. Bolenz C., Cao Y., Arancibia M.F., et al. Intravesical mitomycin C for superficial transitional cell carcinoma. Expert Rev Anticancer Ther 2006, 6(8):1273-1282.
70. Neulander E.Z., Lismer L., Kaneti J. Necrosis of the glans penis: a rare complication of intravesical therapy with mitomycin c. J Urol 2000, 164(4):1306.
71. Kureshi F., Kalaaji A.N., Halvorson L., et al. Cutaneous complications of intravesical treatments for bladder cancer: granulomatous inflammation of the penis following BCG therapy and penile gangrene following mitomycin therapy. J Am Acad Dermatol 2006, 55(2):328-331.
72. Zein T.A., Friedberg N., Kim H. Bone marrow suppression after intravesical mitomycin C treatment. J Urol 1986, 136(2):459-460.
73. Koya M.P., Simon M.A., Soloway M.S. Complications of intravesical therapy for urothelial cancer of the bladder. J Urol 2006, 175(6):2004-2010.
74. Richards B., Tolley D. Benign ulcers after bladder instillation of mitomycin C. Lancet 1986, 1(8471):45.
75. Eijsten A., Knonagel H., Hotz E., et al. Reduced bladder capacity in patients receiving intravesical chemoprophylaxis with mitomycin C. Br J Urol 1990, 66(4):386-388.
76. Pouya M., Van Cangh P.J., Wese F.X., et al. Calcification de la paroi vesicale apres instillation de la mitomycine C. A propos d'une observation. Acta Urol Belg 1995, 63(4):19-21. [in French].
77. Drago P.C., Badalament R.A., Lucas J., et al. Bladder wall calcification after intravesical mitomycin C treatment of superficial bladder cancer. J Urol 1989, 142(4):1071-1072.
78. Alter A.J., Malek G.H. Bladder wall calcification after topical mitomycin C. J Urol 1987, 138(5):1239-1240.
79. Michielsen D., Amy J.J., Coomans D., et al. Mitomycin C and epirubicin: functional bladder damage in rats after repeat intravesical instillations. J Urol 2005, 173(6):2166-2170.